Riamilovir

Riamilovir
Clinical data
Trade namesTriazavirin
Other namesTZV
ATC code
  • None
Legal status
Legal status
  • RU: Rx-only
Identifiers
  • 2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-c] [1,2,4]triazin-7(4H)-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.217.074 Edit this at Wikidata
Chemical and physical data
FormulaC5H4N6O3S
Molar mass228.19 g·mol−1
3D model (JSmol)
  • CSc1[nH]n2c(=O)c(nnc2n1)[N+](=O)[O-]
  • InChI=1S/C5H4N6O3S/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5/h1H3,(H,6,8,9)
  • Key:IDVQGNMSSHPZSJ-UHFFFAOYSA-N

Riamilovir, sold under the brand name Triazavirin, is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical.[1] It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[2]

The principal action of riamilovir is to inhibit the synthesis of viral ribonucleic acid (RNA) and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides.[3][4][5]

  1. ^ "Triazaverin Is Officially Recommended". www.medsintez.com. Retrieved 25 February 2021.
  2. ^ Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4. S2CID 83702396.
  3. ^ Cite error: The named reference pmid20194696 was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference pmid25051708 was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference pmid19275052 was invoked but never defined (see the help page).